Retrospective Analysis of the Safety and Efficacy of High-dose Interleukin-2 After Prior Tyrosine Kinase Inhibitor Therapy in Patients With Advanced Renal Cell Carcinoma

Although tyrosine kinase inhibitors (TKI) are the most common first-line therapy for metastatic renal cell carcinoma, high-dose interleukin-2 (HD-IL2) remains the only agent that provides durable complete responses. The optimal sequence of these agents remains uncertain. This retrospective multi-ins...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Lam, Elaine T., Wong, Michael K. K., Agarwal, Neeraj, Redman, Bruce G., Logan, Theodore, Gao, Dexiang, Flaig, Thomas W., Lewis, Karl, Poust, Jamie, Monk, Paul, Jarkowski, Anthony, Sendilnathan, Arun, Bolden, Marcus, Kuzel, Timothy M., Olencki, Thomas
Formato: Artigo
Idioma:Inglês
Publicado: Lippincott Williams & Wilkins 2014
Assuntos:
Clinical Studies
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4127096/
https://ncbi.nlm.nih.gov/pubmed/25075565
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0000000000000044
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares